SM
RPTX

SG3 Management’s Repare Therapeutics RPTX Stock Holding History

SG3 Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,000
Closed -$105K – 1250
2021
Q3 		$105K Buy
+4,000
New +$129K ﹤0.01% 858

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

SG3 Management's RPTX Position: Q4 2021 in Review

SG3 Management sold out of Repare Therapeutics (RPTX) in Q4 2021, closing a stake of 15,000 shares — an estimated $394K sold.

SG3 Management first reported a position in RPTX in Q3 2021 and held it in 1 quarter. The position peaked at $394K in Q3 2021. 67 funds tracked by Wall St. Rank hold RPTX as of Q4 2021.

  • SG3 Management reported no remaining Repare Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 15,000 Repare Therapeutics shares in Q4 2021, an estimated $394K.
  • SG3 Management first reported a position in Repare Therapeutics in Q3 2021 and held it in 1 quarter.
  • SG3 Management's Repare Therapeutics position peaked at $394K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.